Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an ...
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. CD19/CD20 Bi-Specific CAR-T ...
Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...
National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide Seven days before the first ...
As East Asia prepares to shut down for the Lunar New Year holiday and looks towards the Year of the Snake, it’s time to look back at bitcoin BTC $88,605.45 and the CoinDesk 20 (CD20)’s performance ...
From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients. Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) lived twice as long when treated with ...
Over the last 25 years, since Kohler and Milstein 1 first described making monoclonal antibodies (MAbs), much time has been spent trying to develop these reagents in order to treat human disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results